Forxiga’s acute renal impairment warning added in Korea too
Acute renal impairment will be added in approval standards of antidiabetic SGLT-2 inhibitors, ‘Forxiga(dapagliflozin)’ and ‘Invokana(canagliflozin).’
According to the Ministry of Food and Drug Safety(MFDS) on the 22nd, it prepared for an amendment to approval standards of drugs containing canagl...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
